Aggrastat

Base Information

• Chemical Name: Aggrastat
• CAS No.: 142373-60-2
• Molecular Formula: C22H37ClN2O5S
• Molecular Weight: 477.06
• UNII: IKE1P4X57J
• DSSTox Substance ID: DTXSID70931418
• Wikidata: Q27280770
• NCI Thesaurus Code: C47759
• RXCUI: 253202
• ChEMBL ID: CHEMBL1704
• Mol file: 142373-60-2.mol

Synonyms:Aggrastat;Agrastat;L 700,462;L 700462;L-700,462;L-700462;L700,462;MK 383;MK-383;N-(butylsulfonyl)-O-(4-(4-piperidyl)butyl)-L-tyrosine;tirofiban;tirofiban hydrochloride;tirofiban hydrochloride monohydrate

Chemical Property of Aggrastat

Chemical Property:

• Melting Point: 223-225oC
• Boiling Point: 611.7 °C at 760 mmHg
• Flash Point: 323.7 °C
• PSA: 122.34000
• LogP: 5.48870
• Solubility.: Methanol (Slightly)
• Hydrogen Bond Donor Count: 4
• Hydrogen Bond Acceptor Count: 7
• Rotatable Bond Count: 14
• Exact Mass: 476.2111712
• Heavy Atom Count: 31
• Complexity: 579

Purity/Quality:

99% ^*data from raw suppliers

TirofibanHCl ^*data from reagent suppliers

Safty Information:

• Pictogram(s):  
• Hazard Codes: 

MSDS Files:

SDS file from LookChem

Useful:

• Canonical SMILES: CCCCS(=O)(=O)NC(CC1=CC=C(C=C1)OCCCCC2CCNCC2)C(=O)O.Cl
• Isomeric SMILES: CCCCS(=O)(=O)N[C@@H](CC1=CC=C(C=C1)OCCCCC2CCNCC2)C(=O)O.Cl
• Recent ClinicalTrials: Clinical Trial to Evaluate the Safety of Continuous IV Tirofiban in Acute Ischemic Stroke
• Recent EU Clinical Trials: Facilitation through Aggrastat or cangrelor Bolus and infusion Over prasugreL: a muUlticenter randomized open-label trial in patientS with ST-elevation myocardial inFarction referred for primAry percutaneouS inTERvention.
• Description: Tirofiban was launched as Aggrastat in Switzerland and the US for patients with unstable angina or non-Q-wave myocardial infarction to prevent cardiac ischemic events. Tirofiban is synthesized from (S)-tyrosine by a fourstep process. Tirofiban is a novel highly potent antiplatelet agent that inhibits the interaction of fibrinogen with GPⅡb/Ⅲa, an activated platelet membrane-bound glycoprotein complex. It prevents arterial thrombus formation in a dosedependent manner. Clinical efficacy was highly significant with an absolute and relative risk reduction. In these studies, treatment with tirofiban was well tolerated, without significant adverse effects.
• Uses: Aggrastat (Millot Laboratories, France). Tirofiban Hydrochloride is a selective nonpeptide platelet glycoprotein IIb/IIIa antagonist.
• Therapeutic Function: Fibrinogen receptor antagonist